Chronic myelogenous leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the uncontrolled growth of abnormal white blood cells, known as myeloid cells. CML is relatively rare compared to other types of leukemia, accounting for approximately 15% of all adult leukemia cases. The prevalence of CML varies across different populations and regions.
According to available data, the annual incidence rate of CML is estimated to be around 1 to 2 cases per 100,000 individuals. This means that in a population of 1 million people, there may be approximately 10 to 20 new cases of CML each year. The prevalence of CML, which refers to the total number of individuals living with the disease at a given time, is estimated to be around 10 to 15 cases per 100,000 individuals.
It is important to note that the prevalence of CML has increased over the years, mainly due to advancements in diagnostic techniques and improved survival rates. The introduction of targeted therapies, such as tyrosine kinase inhibitors, has significantly improved the prognosis for individuals with CML. Early detection and timely treatment play a crucial role in managing the disease and improving patient outcomes.
by Diseasemaps